2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

2083 Concurrent lymphoid malignancies do not adversely affect clinical outcomes of myeloid neoplasms

Tatsuro Hirao, MD, Rashmi Kanagal-Shamanna, MD2, Sherry Pierce, BSN, RN3, Jairo Matthews, BA4, Zongrui Li5, Nitin Jain, MD6, Elias Jabbour, MD7, Hagop Kantarjian, MD8, Tapan Kadia I, MD9, Naveen Pemmaraju, MD10, William G. Wierda, MD, PhD11, Sattva S Neelapu Sr, MD12, Courtney DiNardo, MD, MSCE13, Krina Patel Jr, MD, MSc14, Carlos Bueso-Ramos, M.D., Ph.D.15, Guillermo Garcia-Manero, MD16, Koichi Takahashi, MD,PhD17
1 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Background: With the advent of diagnostic technologies, the detection of concurrent myeloid and lymphoid neoplasms is increasing. Diagnosis of concurrent myeloid and lymphoid neoplasms poses unique clinical challenges, as it is often unclear which malignancy is contributing to the disease phenotype and which disease should be prioritized for treatment. In addition, patients with concurrent hematologic malignancies are frequently excluded from clinical trials. Here, we characterized the genetic and clinical features of patients with concurrent myeloid and lymphoid neoplasms.

Methods:
We retrospectively studied patients with a diagnosis of concurrent myeloid and lymphoid neoplasms between 2012 and 2026. Patients with therapy-related myeloid neoplasms (t-MNs) arising after cytotoxic treatment for a lymphoid neoplasm were excluded.

Results: During the study period, we identified 234 patients with malignancies of both lineages, of whom 90 were excluded due to t-MN diagnosis, leaving 144 patients for subsequent analysis. Median age at the time of diagnosis was 70.0 years (IQR, 65.8-76.9) and 103 patients (71.5%) were male. Among the myeloid neoplasms, MDS and MDS/MPN were most common (n=66; 45.8%), followed by MPN (n=38; 26.4%), AML (n=28; 19.4%), and CML (n=12; 8.3%). CLL was the most frequent co-occurring lymphoid neoplasm (n=45; 31.3%), followed by MM (n=35; 24.3%), MGUS (n=35; 24.3%), FL (n=8; 5.6%), large B-cell lymphoma (n=7; 4.9%), mantle cell lymphoma (n=5; 3.5%), PTCL (n=2; 1.4%), and other low-grade lymphoma (n=7; 4.9%). The combination of MDS or MDS/MPN with plasma cell neoplasms (PCN) consisted of 25% of the co-occurrence (n=36).
88 patients underwent targeted panel NGS analysis, which identified recurrent mutations in TET2 (n=40, 45.5%), SRSF2 (n=24, 27.3%), ASXL1 (n=22, 25%), RUNX1 (n=18, 20.5%), and SF3B1 (n=16, 18.2%). Sixteen patients were found to have both myeloid and lymphoid-associated mutations. For instance, in patients with MDS/AML and CLL, co-occurrence of BCOR or TP53, and IGLL5, KMT2D was detected. Another patient with MDS/MPN and FL, SRSF2, ZRSR2, and PAX5 was detected. VAF (variant allele frequency) of myeloid mutations were significantly higher compared to lymphoid mutations (myeloid vs. lymphoid, VAF 31.1% [IQR: 8.5-36.4) vs. 5.0% [IQR: 2.8-14.5), P = 0.04), suggesting that lymphoid clones are typically subclonal.  
Overall survival (OS) from concurrent diagnosis did not differ significantly by co-occurring lymphoid neoplasm subtype (P=0.46): 28.3 months (95% CI, 22.0-NR) for lymphoma, 34.0 months (95% CI, 19.0-94.6) for CLL, and 38.4 months (95% CI, 26.1-NR) for PCN. In contrast, when stratified by myeloid neoplasms, median OS differed significantly (P<0.001): 19.0 months (95% CI, 8.7-NR) for AML, 27.9 months (95% CI, 22.0-38.4) for MDS or MDS/MPN, and 94.6 months (95% CI, 70.9-NR) for MPN, indicating that prognosis is mainly determined by the myeloid neoplasm diagnosis. Compared with 12,161 control patients with isolated myeloid neoplasms diagnosed during the same period, concurrent lymphoid neoplasms were not associated with inferior OS: 19.0 (95% CI: 8.7-NR) vs 16.9 (95% CI: 16.4-17.7) months for AML (P = 0.86), 27.1 (95% CI, 18.6-NR) vs 27.1 (95% CI, 25.4-29.0) months for MDS (P = 0.91), and 38.4 (95% CI, 26.8-NR) vs 34.1 (95% CI, 30.7-37.8) months for MDS/MPN (P = 0.48). Complete remission rate following induction therapy was also similar in AML patients between concurrent vs. control groups (75% vs. 69%, P = 0.25). Despite similar clinical outcomes, participation rate in clinical trial was significantly lower in the concurrent group (20/94, 21.3%) than in controls (5,675/12,161, 46.7%; P<0.001). Seventeen patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), and 6 achieved sustained remission of both neoplasms. Four patients relapsed with the myeloid neoplasm alone, and notably, small numbers of aberrant plasma cells remained detectable after allo-HSCT in 3 patients. Both malignancy relapsed in 4 patients.

Conclusion: Concurrent myeloid and lymphoid neoplasm most commonly involve MDS or MDS/MPN with PCN. Genetically, myeloid clones tend to be the dominant clone, whereas lymphoid mutations are typically subclonal. Importantly, concurrent lymphoid malignancies do not adversely affect treatment response or survival of patients with myeloid neoplasms, suggesting that these patients should not be routinely excluded from clinical trials.

Tatsuro Hirao, MD: No relevant conflicts of interest to declare.